A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

- Relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy
regimen that included an anti-CD20 monoclonal antibody and for which no other more
appropriate treatment option exists as determined by the investigator

- Histologically documented CD20-positive lymphoma as determined by the local laboratory

- Fluorodeoxyglucose-avid lymphoma (i.e., PET-positive lymphoma)

- At least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by
CT scan or magnetic resonance imaging [MRI])

- Availability of a representative tumor specimen and the corresponding pathology report
for retrospective central confirmation of the diagnosis of FL

- Agreement to comply with all local requirements of the lenalidomide risk minimization
plan

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use two adequate methods of contraception, including at
least one method with a failure rate of <1% per year, for at least 28 days prior to
Day 1 of Cycle 1, during the treatment period (including periods of treatment
interruption), and for at least 18 months after the last dose of study treatment

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures and agreement to refrain from donating sperm for at least 3
months after the last dose of study treatment

Exclusion Criteria:

- Grade 3b follicular lymphoma

- History of transformation of indolent disease to diffuse large B-cell lymphoma (DLBCL)

- Known CD20-negative status at relapse or progression

- Central nervous system lymphoma or leptomeningeal infiltration

- Prior allogeneic stem-cell transplantation (SCT)

- Completion of autologous SCT within 100 days prior to Day (D) 1 of Cycle (C) 1

- Prior standard or investigational anti-cancer therapy as specified in protocol

- History of resistance to lenalidomide or response duration of <1 year

- Treatment with systemic immunosuppressive medications

- History of solid organ transplantation

- Clinically significant toxicity from prior therapy that has not resolved to Grade <=2
(according to the National Cancer Institute Common Terminology Criteria for Adverse
Events [NCI CTCAE], v4.0) prior to Day 1 of Cycle 1

- History of erythema multiforme, Grade >= 3 rash, or blistering following prior
treatment with immunomodulatory derivatives such as thalidomide and lenalidomide

- Active bacterial, viral, fungal, or other infection

- Positive for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody
(HBcAb), or hepatitis C virus (HCV) antibody at screening

- Known history of HIV positive status

- History of progressive multifocal leukoencephalopathy

- History of autoimmune disease

- Contraindication to treatment for TE prophylaxis

- Grade <= 2 neuropathy

- History of other malignancy that could affect compliance with the protocol or
interpretation of results

- Evidence of any significant, uncontrolled concomitant disease

- Inadequate hematologic function (unless due to underlying lymphoma)

- Abnormal laboratory values (unless due to underlying lymphoma)

- Pregnant or lactating or intending to become pregnant during the study